Skip to content

Cohort study of improving cognitive function in depressed patients with different doses of buspirone hydrochloride tablets

Cohort study of improving cognitive function in depressed patients with different doses of buspirone hydrochloride tablets

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106000
Enrollment
Unknown
Registered
2025-07-15
Start date
2025-07-24
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychiatry and Mental Health

Interventions

control group:none
treatment group 2:None

Sponsors

West China School of Medicine/West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Conform to The diagnostic criteria for depression in The diagnostic and statistical manual of mental disorders-5 (DSM-5); 2. Male or female, outpatients or inpatients; 3. Han ethnicity; 4. Age over 18 years old and under 65 years old; 5. Patients who sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women who are unwilling to take contraceptive measures during the study period; 2. Patients who are allergic to buspirone or have one of the contraindications for buspirone; 3. Patients who suffer from severe or unstable diseases and are judged by the researchers as unsuitable to participate in this study; 4. Patients with a history of any neurological diseases (including epileptic seizures, brain injury, multiple sclerosis, degenerative diseases such as acute lateral sclerosis, Parkinson's disease and movement disorders, etc.); 5. Those diagnosed with other mental disorders; 6. Those who have regularly used buspirone or tandospirone, antipsychotic drugs, mood stabilizers, antiepileptic drugs or have used long-acting preparations within two weeks; 7. Those who are treated with two or more antidepressant drugs; 8. Patients who are currently undergoing or have received ECT treatment within the past six months; 9. Professional drivers or patients engaged in dangerous mechanical operations; 10. Patients who have participated in other clinical studies and taken drugs provided by the sponsor within the last 3 months; 11. Patients with clinically significant electrocardiogram or laboratory test abnormalities; Patients with acute angle-closure glaucoma; 13. Patients with myasthenia gravis; 14. Those with serious suicidal attempts; 15. Or those with severe impulses.

Design outcomes

Primary

MeasureTime frame
Depression;Anxiety;Clinical efficacy;Neurocognitive function;

Countries

China

Contacts

Public ContactXiaohong Ma

West china hospital, Sichuan University

maxiaohong@scu.edu.cn+86 189 8060 2101

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026